DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
” - 2 Dr - 2 Phil Dormitzer - 2 stow - 1 Shingrix - 1 that’s - 1 Paul Harrison - 1 ” Harrison - 1
Top related locs:
United States British Europe Japan U.S Massachusetts BioNTech New York
Top related orgs:
GSK - 2 Pfizer - 2 Moderna - 2 CNN - 1 US Centers for Disease Control - 1 Nature - 1 GlaxoSmithKline - 1 University of Oxford - 1

Search resuls for: "Dormitzer"


5 mentions found


☆ Shingles vaccines may reduce dementia risk, two large new studies suggest
  + stars: | 2024-07-30 | by ( Brenda Goodman | ) edition.cnn.com   time to read: +9 min
In 2017, a stronger vaccine, Shingrix, became available. “While research into whether vaccines affect dementia risk continues, people should be aware that there are other factors that have definitively been linked to an increased dementia risk. This study also found that the new shingles vaccine was associated with a larger degree of benefit than the older one. Although the findings are intriguing, the association needs more study before researchers can know for sure that the shingles vaccine is definitively behind the benefit. So for the time being, the best reason to get a shingles vaccine is still to avoid the misery of shingles.
Persons: stow, Shingrix, that’s, ”, Paul Harrison, ” Harrison, Dr, Andrew Doig, ” Doig, it’s, Sheona Scales, Scales, Sanjay Gupta, Phil Dormitzer Organizations: CNN, US Centers for Disease Control, Nature, GlaxoSmithKline, GSK, University of Oxford, University of Manchester, Alzheimer’s Research, Alzheimer’s Association International Conference, Oxford, CNN Health Locations: United States
☆ FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
  + stars: | 2024-06-07 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
But the virus can also cause severe illness in adults 50 and up — or even younger — with underlying chronic conditions such as asthma, diabetes and congestive heart failure. GSK's shot won't reach that new patient population just yet. Safety data in adults ages 50 to 59 was also consistent with data in adults 60 and above, according to GSK. Regulatory agencies in Europe, Japan and other areas are currently reviewing GSK's application to expand Arexvy's approval to high-risk adults ages 50 to 59. GSK's shot is approved in nearly 50 countries, a spokesperson for the company told CNBC.
Persons: Phil Dormitzer, Dormitzer, Luke Miels, Arexvy, GSK's Organizations: Drug Administration, GSK, FDA, Centers for Disease Control, CNBC, CDC, Pfizer, Moderna, U.S Locations: British, Europe, Japan
☆ Years of Research Laid the Groundwork for Speedy COVID-19 Shots
  + stars: | 2023-10-02 | by ( Associated Press | Oct. | At P.M. | ) www.usnews.com   time to read: +7 min
The Nobel Prize in Medicine was awarded Monday to two scientists whose work led to the mRNA vaccines against COVID-19. As countries prepared to roll out those shots, The Associated Press took a look at how the vaccines were developed so quickly. ___How could scientists race out COVID-19 vaccines so fast without cutting corners? A head start helped -- over a decade of behind-the-scenes research that had new vaccine technology poised for a challenge just as the coronavirus erupted. Both shots — one made by Pfizer and BioNTech, the other by Moderna and the National Institutes of Health — are so-called messenger RNA, or mRNA, vaccines, a brand-new technology.
Persons: Dr, Anthony Fauci, Buddy Creech, ” Creech, Tal Zaks, ”, Drew Weissman, Weissman, Katalin, Philip Dormitzer, Barney Graham’s, ” Fauci, Graham, Jason McLellan, hadn't, “, ” Graham, Germany’s, Pfizer’s Dormitzer, Ugur Sahin Organizations: Medicine, COVID, Associated Press, Vanderbilt University, Infectious Diseases Society of America, Pfizer, BioNTech, Moderna, National Institutes of Health, NIH, University of Pennsylvania, Penn, NIH’s Vaccine Research Center, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Department of Science Education, AP Locations: U.S, Massachusetts, BioNTech, New York, China
☆ We're closer to getting the first new pill to treat UTIs in over 20 years
  + stars: | 2022-11-03 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +4 min
It would be the first new pill to treat uncomplicated UTIs in 20 years, GSK said. The drug, called gepotidacin, could become the first new oral antibiotic for uncomplicated UTIs in more than two decades, according to the company. GSK's drug was tested in uncomplicated UTIs, which are restricted to the the bladder and urethra and are generally less serious than complicated UTIs. On Thursday, GSK said two studies enrolled over 3,000 patients with uncomplicated UTIs. GSK, on the other hand, paid $66 million in September to license another antibiotic program being tested to treat complicated UTIs.
☆ New RSV vaccines may soon put an end to rough seasons
  + stars: | 2022-10-31 | by ( Brenda Goodman | ) edition.cnn.com   time to read: +15 min
The monoclonal antibody, Synagis, is given monthly during RSV season to protect preemies and other high-risk babies. In the failed RSV vaccine trial, the chemical the researchers used to deactivate the virus denatured its proteins – essentially flattening them. Four companies have RSV vaccines for adults in the final phases of human trials: Pfizer and GSK are testing vaccines for pregnant women as well as seniors. Janssen, Pfizer and GSK each appear effective at preventing infections in adults for the first RSV season after the vaccine. The vaccines for pregnant women are meant to get newborns through their first RSV season.
0 next >>
Total: 5